Humoral and mucosal immunity in infants induced by three sequential inactivated poliovirus vaccine-live attenuated oral poliovirus vaccine immunization schedules

John F. Modlin, Neal A Halsey, Mary Lou Thoms, Carlton K. Meschievitz, Peter A. Patriarca

Research output: Contribution to journalArticle

Abstract

The relative immunity induced by sequential administration of inactivated poliovirus vaccine (IPV) produced in human diploid cells and live attenuated oral poliovirus vaccine (OPV) was evaluated by randomization of 510 infants to receive IPV and OPV sequentially according to one of three experimental schedules, IPV only, or OPV only. The antibody response to two IPV doses was lower than expected. However, for each of the IPV-OPV sequential schedules, the first OPV dose significantly enhanced zeroconversion rates and geometric mean microneutralization antibody titers. Three months after the final dose, 96%-99%, 99%-100%, and 81%-100% of infants had antibodies to poliovirus types 1, 2, and 3, respectively, and subjects with two or more prior OPV doses were significantly less likely than those with none or one prior OPV dose to excrete virus in feces after an OPV challenge. Sequential IPV-OPV immunization is now recommended for routine use in the United States. The optimal schedule consists of two IPV doses followed by two OPV doses.

Original languageEnglish (US)
JournalJournal of Infectious Diseases
Volume175
Issue number2 SUPPL.
StatePublished - 1997
Externally publishedYes

Fingerprint

Inactivated Poliovirus Vaccine
Oral Poliovirus Vaccine
Immunization Schedule
Mucosal Immunity
Attenuated Vaccines
Humoral Immunity
Poliovirus
Appointments and Schedules
Antibodies
Random Allocation
Diploidy
Feces
Antibody Formation
Immunity
Immunization

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

Humoral and mucosal immunity in infants induced by three sequential inactivated poliovirus vaccine-live attenuated oral poliovirus vaccine immunization schedules. / Modlin, John F.; Halsey, Neal A; Thoms, Mary Lou; Meschievitz, Carlton K.; Patriarca, Peter A.

In: Journal of Infectious Diseases, Vol. 175, No. 2 SUPPL., 1997.

Research output: Contribution to journalArticle

@article{edfc99ff0b8545abbad8c8e94ca6ff6b,
title = "Humoral and mucosal immunity in infants induced by three sequential inactivated poliovirus vaccine-live attenuated oral poliovirus vaccine immunization schedules",
abstract = "The relative immunity induced by sequential administration of inactivated poliovirus vaccine (IPV) produced in human diploid cells and live attenuated oral poliovirus vaccine (OPV) was evaluated by randomization of 510 infants to receive IPV and OPV sequentially according to one of three experimental schedules, IPV only, or OPV only. The antibody response to two IPV doses was lower than expected. However, for each of the IPV-OPV sequential schedules, the first OPV dose significantly enhanced zeroconversion rates and geometric mean microneutralization antibody titers. Three months after the final dose, 96{\%}-99{\%}, 99{\%}-100{\%}, and 81{\%}-100{\%} of infants had antibodies to poliovirus types 1, 2, and 3, respectively, and subjects with two or more prior OPV doses were significantly less likely than those with none or one prior OPV dose to excrete virus in feces after an OPV challenge. Sequential IPV-OPV immunization is now recommended for routine use in the United States. The optimal schedule consists of two IPV doses followed by two OPV doses.",
author = "Modlin, {John F.} and Halsey, {Neal A} and Thoms, {Mary Lou} and Meschievitz, {Carlton K.} and Patriarca, {Peter A.}",
year = "1997",
language = "English (US)",
volume = "175",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "2 SUPPL.",

}

TY - JOUR

T1 - Humoral and mucosal immunity in infants induced by three sequential inactivated poliovirus vaccine-live attenuated oral poliovirus vaccine immunization schedules

AU - Modlin, John F.

AU - Halsey, Neal A

AU - Thoms, Mary Lou

AU - Meschievitz, Carlton K.

AU - Patriarca, Peter A.

PY - 1997

Y1 - 1997

N2 - The relative immunity induced by sequential administration of inactivated poliovirus vaccine (IPV) produced in human diploid cells and live attenuated oral poliovirus vaccine (OPV) was evaluated by randomization of 510 infants to receive IPV and OPV sequentially according to one of three experimental schedules, IPV only, or OPV only. The antibody response to two IPV doses was lower than expected. However, for each of the IPV-OPV sequential schedules, the first OPV dose significantly enhanced zeroconversion rates and geometric mean microneutralization antibody titers. Three months after the final dose, 96%-99%, 99%-100%, and 81%-100% of infants had antibodies to poliovirus types 1, 2, and 3, respectively, and subjects with two or more prior OPV doses were significantly less likely than those with none or one prior OPV dose to excrete virus in feces after an OPV challenge. Sequential IPV-OPV immunization is now recommended for routine use in the United States. The optimal schedule consists of two IPV doses followed by two OPV doses.

AB - The relative immunity induced by sequential administration of inactivated poliovirus vaccine (IPV) produced in human diploid cells and live attenuated oral poliovirus vaccine (OPV) was evaluated by randomization of 510 infants to receive IPV and OPV sequentially according to one of three experimental schedules, IPV only, or OPV only. The antibody response to two IPV doses was lower than expected. However, for each of the IPV-OPV sequential schedules, the first OPV dose significantly enhanced zeroconversion rates and geometric mean microneutralization antibody titers. Three months after the final dose, 96%-99%, 99%-100%, and 81%-100% of infants had antibodies to poliovirus types 1, 2, and 3, respectively, and subjects with two or more prior OPV doses were significantly less likely than those with none or one prior OPV dose to excrete virus in feces after an OPV challenge. Sequential IPV-OPV immunization is now recommended for routine use in the United States. The optimal schedule consists of two IPV doses followed by two OPV doses.

UR - http://www.scopus.com/inward/record.url?scp=16944367385&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16944367385&partnerID=8YFLogxK

M3 - Article

C2 - 9203721

AN - SCOPUS:16944367385

VL - 175

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 2 SUPPL.

ER -